INTENSITY THERAPEUTICS, INC. (INTS) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 2.25M USD | Liabilities, Current |
| Cash and equivalents | 9.53M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.25M | $9.53M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $2.24M | $10.24M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $2.15M | $11.92M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $2.28M | $7.07M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $2.16M | $2.22M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $2.63M | $929.00K | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $1.75M | $2.59M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $2.32M | $2.78M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $3.20M | $3.24M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $2.52M | $7.46M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $3.96M | $8.56M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $723.97K | $6.69M | $8.96M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $3.06M | $135.76K | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $8.56M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $6.82M | $1.31M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |